Finance

Lists
688513:SHA
Chengdu Easton Biopharmaceuticals Co Ltd
CNÂ¥45.39
-1.63%
(-0.75) 1D
Sep 8, 3:00:04 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688513...
Open
CNÂ¥46.32
High
CNÂ¥46.50
Low
CNÂ¥44.91
Mkt. cap
7.86B
Avg. vol.
2.62M
Volume
1.80M
Dividend
1.08%
Quarterly dividend
CNÂ¥0.12
Ex-dividend date
Jun 2, 2026
P/E ratio
28.35
52-wk high
CNÂ¥80.48
52-wk low
CNÂ¥40.25
EPS
CNÂ¥1.60
No. of employees
1K
Open
CNÂ¥46.32
High
CNÂ¥46.50
Low
CNÂ¥44.91
Mkt. cap
7.86B
Avg. vol.
2.62M
Volume
1.80M
Dividend
1.08%
Quarterly dividend
CNÂ¥0.12
Ex-dividend date
Jun 2, 2026
P/E ratio
28.35
52-wk high
CNÂ¥80.48
52-wk low
CNÂ¥40.25
EPS
CNÂ¥1.60
No. of employees
1K
About Chengdu Easton Biopharmaceuticals Co Ltd
CEO-
Employees1.42K
FoundedJun 1, 2009
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
364.69M
312.26M
326.26M
332.64M
Cost of goods sold
87.18M
88.47M
73.62M
82.94M
Cost of revenue
87.18M
88.47M
73.62M
82.94M
Research and development expenses
54.95M
79.44M
72.66M
77.99M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
136.71M
128.80M
143.86M
107.14M
Operating expense
197.59M
214.09M
212.02M
195.99M
Total operating expenses
284.77M
302.56M
285.64M
278.93M
Operating income
79.91M
9.70M
40.62M
53.71M
Other non operating income
-228.90K
230.85K
-519.09K
493.27K
EBT including unusual items
92.35M
57.56M
47.40M
86.84M
EBT excluding unusual items
79.77M
51.53M
41.48M
54.72M
Income tax expense
8.76M
4.15M
4.12M
18.02M
Effective tax rate
9.49%
7.21%
8.69%
20.75%
Other operating expenses
4.49M
8.00M
-4.46M
11.52M
Net income
83.59M
63.90M
50.83M
78.92M
Net profit margin
22.92%
20.46%
15.58%
23.73%
Earnings per share
-
-
-
-
Interest and investment income
733.65K
42.65M
1.95M
2.46M
Interest expense
-615.69K
-622.07K
-575.93K
-792.69K
Net interest expenses
117.96K
42.02M
1.38M
1.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
100.25M
32.44M
63.37M
81.43M
Gain or loss from assets sale
-
-29.35K
-
-18.53K
AI content may include mistakes. Learn more
Google apps